Bristol Vanlev OCTAVE Trial Will Compare Angioedema To ACE Inhibitors
Executive Summary
Bristol's effort to resurrect the Vanlev NDA via the 25,000-patient OCTAVE trial will produce "the best look at angioedema for ACE inhibitors that has ever been compiled," Bristol VP-Corporate Development for the Worldwide Medicines Group Andrew Bodnar, MD, told a July 20 quarterly earnings conference call.